EPL Limited has received ‘No Objection’ letters from both the BSE Limited and the National Stock Exchange of India Limited (NSE) for its proposed scheme of amalgamation with Indovida India Private Limited. This marks a significant regulatory milestone, as the company moves closer to the finalization of the merger. The letters, dated October 19, 2026, confirm that the exchanges have no adverse observations regarding the scheme.
Key Regulatory Approval Secured for Amalgamation
EPL Limited has announced a major step forward in its strategic initiative to amalgamate with Indovida India Private Limited. The company has received ‘No Objection’ letters from both the BSE Limited and the National Stock Exchange of India Limited (NSE). These letters, both dated October 19, 2026, indicate that the stock exchanges have no adverse observations concerning the proposed scheme of amalgamation.
Scheme of Amalgamation Progress
The scheme, which involves the merger of Indovida India Private Limited into EPL Limited by way of absorption, is proceeding under Sections 230 to 232 of the Companies Act, 2013. The company had initially filed the necessary applications with BSE and NSE on April 22, 2026, seeking their ‘No Objection’ to the merger. The receipt of these observation letters is a critical prerequisite for proceeding with the next stages of regulatory approvals.
Next Steps and Timeline
The observation letters from BSE and NSE are valid for six months from their issue date, meaning the scheme must be submitted to the National Company Law Tribunal (NCLT) within this period. EPL Limited will continue to ensure compliance with all applicable regulations and will make the observation letters available on its website, as well as on the stock exchanges’ websites.
This development is a positive indicator for the potential synergies and strengthened market position anticipated from the amalgamation.
Source: BSE
